505 related articles for article (PubMed ID: 34090962)
1. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
[TBL] [Abstract][Full Text] [Related]
2. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
Jang Y; Shin JS; Lee MK; Jung E; An T; Kim UI; Kim K; Kim M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557278
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
Elife; 2021 Oct; 10():. PubMed ID: 34617885
[TBL] [Abstract][Full Text] [Related]
5. Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture.
Bakovic A; Risner K; Bhalla N; Alem F; Chang TL; Weston WK; Harness JA; Narayanan A
Viruses; 2021 Feb; 13(2):. PubMed ID: 33572467
[TBL] [Abstract][Full Text] [Related]
6. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
7. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection.
Monteil V; Dyczynski M; Lauschke VM; Kwon H; Wirnsberger G; Youhanna S; Zhang H; Slutsky AS; Hurtado Del Pozo C; Horn M; Montserrat N; Penninger JM; Mirazimi A
EMBO Mol Med; 2021 Jan; 13(1):e13426. PubMed ID: 33179852
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
Raymonda MH; Ciesla JH; Monaghan M; Leach J; Asantewaa G; Smorodintsev-Schiller LA; Lutz MM; Schafer XL; Takimoto T; Dewhurst S; Munger J; Harris IS
Virology; 2022 Jan; 566():60-68. PubMed ID: 34871905
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of itraconazole against SARS-CoV-2.
Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
[TBL] [Abstract][Full Text] [Related]
12. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
Pohl MO; Busnadiego I; Marrafino F; Wiedmer L; Hunziker A; Fernbach S; Glas I; Moroz-Omori EV; Hale BG; Caflisch A; Stertz S
J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34319869
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate inhibits SARS-CoV-2 virus replication "in vitro".
Caruso A; Caccuri F; Bugatti A; Zani A; Vanoni M; Bonfanti P; Cazzaniga ME; Perno CF; Messa C; Alberghina L
J Med Virol; 2021 Mar; 93(3):1780-1785. PubMed ID: 32926453
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT
Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
[TBL] [Abstract][Full Text] [Related]
16. The
Urda L; Kreuter MH; Drewe J; Boonen G; Butterweck V; Klimkait T
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062310
[TBL] [Abstract][Full Text] [Related]
17. Sensitive visualization of SARS-CoV-2 RNA with CoronaFISH.
Rensen E; Pietropaoli S; Mueller F; Weber C; Souquere S; Sommer S; Isnard P; Rabant M; Gibier JB; Terzi F; Simon-Loriere E; Rameix-Welti MA; Pierron G; Barba-Spaeth G; Zimmer C
Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 34996842
[TBL] [Abstract][Full Text] [Related]
18. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
White KM; Rosales R; Yildiz S; Kehrer T; Miorin L; Moreno E; Jangra S; Uccellini MB; Rathnasinghe R; Coughlan L; Martinez-Romero C; Batra J; Rojc A; Bouhaddou M; Fabius JM; Obernier K; Dejosez M; Guillén MJ; Losada A; Avilés P; Schotsaert M; Zwaka T; Vignuzzi M; Shokat KM; Krogan NJ; García-Sastre A
Science; 2021 Feb; 371(6532):926-931. PubMed ID: 33495306
[TBL] [Abstract][Full Text] [Related]
19. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.
Pirzada RH; Haseeb M; Batool M; Kim M; Choi S
Cells; 2021 Apr; 10(5):. PubMed ID: 33946869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
